Data show Roche's new subcutaneous form of Herceptin is preferred by patients and could save resources in Europe's hospitals; Use of new Herceptin formulation reduced the time needed for pharmacists and doctors to treat patients; Subcutaneous Herceptin al
Basel - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented data from the PrefHer study at the European Cancer Congress (ECC) in Amsterdam showing that its new, EU-approved subcutaneous formulation of Herceptin (trastuzumab) is preferred by patients and healthcare teams alike, reduces the time patients spend receiving treatment, can free up healthcare providers' time and helps improve health centre efficiency. PrefHer is one of the first ever studies to examine patient preference for a cancer therapy.
"Living with breast cancer is very challenging and being able to lead as normal a life as possible during treatment is incredibly important." said Hal Barron, MD, Roche's Chief Medical Officer and Head of Global Product Development. "Patients prefer the subcutaneous formulation of Herceptin to the intravenous form because they spend less time in hospital and it also saves valuable time for healthcare providers."
More than 80,000 patients receive Herceptin each year in Europe, and patients may be treated with the medicine for several years. In the PrefHer study, use of the subcutaneous formulation cut the time patients with early breast cancer spent in chemotherapy suites by more than half (58%), potentially providing capacity and resource savings for hospitals and healthcare teams.
Additionally, almost all patients (92%) preferred the less invasive subcutaneous formulation. Overwhelmingly, this was because patients spent less time at the treatment centre and felt they experienced less pain or irritation than with the intravenous form.
The data are featured in a poster presentation1 today at ECC in Amsterdam by Erwin de Cock from the United BioSource Corporation in Barcelona, Spain (Abstract P128, Monday 30 September, Hall 4).
The PrefHer patient preference data2 were presented on Saturday by Prof. Lesley Fallowfield, from Brighton & Sussex Medical School, University of Sussex, in Falmer, UK (Abstract P719, Saturday 28 September, Hall 4).